Navigation Links
The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the atrial fibrillation drug market will experience continued growth through the rest of the decade, increasing from $3.4 billion in 2012 to $8.6 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, generic entry of Boehringer Ingelheim's Pradaxa and Bayer/Janssen's Xarelto will result in contraction of the atrial fibrillation market in the latter part of the 2012 to 2022 forecast period, with the market contracting to $8.1 billion in 2022.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Atrial Fibrillation, which will be published in the days ahead, finds that the novel oral anticoagulants developed for the prevention of stroke in atrial fibrillation patients will continue to drive market growth, accounting for approximately 70 percent market share in 2022. Despite a slow start following its 2013 launch, Bristol-Myers Squibb/Pfizer's Eliquis is expected to be the sales-leading anticoagulant and will garner more than $2.7 billion in 2022. The use of the new anticoagulants will result in a steep decline in sales of warfarin (Bristol-Myers Squibb's Coumadin, Eisai's Warfarin, generics) and other currently available vitamin K antagonists. The anticipated launch of Armetheon's tecarfarin as an anticoagulant therapy for atrial fibrillation patients with mechanical heart valves in the United States will see vitamin K antagonists remain a notable presence in the atrial fibrillation drug market.

The report also reveals that ChanRx's oral cardioversion agent vanoxerine will become the sales-leading antiarrhythmic drug during the forecast period, despite only launching in 2018. Vanoxerine's high efficacy, combined with its strong safety profile, will ensure strong uptake both as a cardioversion agent and as a pill-in-the-pocket therapy.

"Despite initial poor uptake following its launch, we forecast that Eliquis will become the market leader owing to its superior clinical trial data. Eliquis remains the only agent to demonstrate increased efficacy and lower rates of major bleeding versus warfarin," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "Continued strong uptake of Bayer/Janssen's Xarelto, due largely to its once-daily dosing, will see Xarelto become the second best-selling agent with peak-year sales in excess of $2 billion prior to its patent expiration in the United States in 2021."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Announces Acquisition of Rights to Novel LAMA Respiratory Compound from Pfizer
2. BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
3. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
4. The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
5. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
6. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
7. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
8. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
9. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
10. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
11. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, ... to and which He does not. Yisrayl says with so many titles and names ... name, but he says with a little Scripture, backed with a lot of research, the ...
(Date:4/28/2017)... ... 28, 2017 , ... Intellitec Solutions announced the publication of ... Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software package. With ... care, Brooke Grove now has the capability to achieve its goal for a ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor ... leant his presence to an educational purpose as the host of the “Informed” series. ... cancer. In a recent episode, the series focuses on thyroid cancer. , Although thyroid ...
Breaking Medicine News(10 mins):